Clairfield advises the management of Zambon S.p.A. in the acquisition of Breath Therapeutics

Zambon, an Italian pharmaceutical multinational, acquired the biotech Breath Therapeutics at an initial price of 140 million euros and with the possibility of reaching a total of 500 million euros at the achievement of regulatory and commercial objectives.